Fadi Taza MD
Hematologic Oncology
Hematology and Oncology Fellow at Indiana University
Join to View Full Profile
1400 N Ritter Ave Ste 340Indianapolis, IN 46219
Phone+1 317-355-5870
Dr. Taza is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Fadi Taza is an oncologist in Indianapolis, IN. Dr. taza received Dr. Tazas medical degree from Damascus University Faculty of Medicine and has been in practice 3 years. Dr. taza specializes in hematologic oncology. Dr. taza has more than 10 publications and over 100 citings.
Education & Training
Damascus University Faculty of MedicineClass of 2015
Certifications & Licensure
IN State Medical License 2021 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 6 citationsCo-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.Jacob J Orme, Fadi Taza, Navonil De Sarkar, Alok K Tewari, Syed Arsalan Naqvi
European Urology Oncology. 2024-08-01 - 10 citationsMaintenance Oral Etoposide After High-Dose Chemotherapy (HDCT) for Patients With Relapsed Metastatic Germ-Cell Tumors (mGCT).Fadi Taza, Rafat Abonour, Mohammad Abu Zaid, Sandra K Althouse, Bilal Anouti
Clinical Genitourinary Cancer. 2023-04-01 - 31 citationsDifferential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate CancerFadi Taza, Albert E Holler, Wei Fu, Hao Wang, Nabil Adra
JCO Precision Oncology. 2021-07-22
Abstracts/Posters
- Salvage high-dose chemotherapy (HDCT) for relapsed primary mediastinal nonseminomatous germ-cell tumors (PMNSGCT)Taza F, Abonour R, Althouse S, Ashkar R, Abu Zaid M, Hanna N, Kessler K, Adra N, Einhorn L., 2022 ASCO Annual Meeting - Chicago, Illinois
- Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancerTaza F, Holler AE, Adra N, Ashkar R, Sokolova AO, Kessel A, Nafissi N, Barata P, Bastos D, Smaletz O, Berchuck JE, Aggarwal R, Vlachostergios PJ, Su C, Marshall CH, An..., 2021 GU ASCO Annual Meeting- San Francisco, California
- The prognostic value of teratoma in the primary tumor and postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) specimens in patients with germ cell tumors...Taza F, Chovanec M, Snavely A, Adra N, Hanna N, Cary C, Masterson T, Einhorn L, Albany C., 2018 ASCO Annual Meeting- Chicago, IL
- Join now to see all
Lectures
- Retroperitoneal cancer viability after postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in good risk germ cell tumors (GCTs).2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- The prognostic value of teratoma in the primary tumor and postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) specimens in patients with germ cell tumors...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Professional Memberships
- Member
External Links
- Google Schoalrhttps://scholar.google.com/citations?user=SX_UA5oAAAAJ&hl=en
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
